Follow-up of multicentric HCC according to the mRECIST criteria: role of 320-Row CT with semi-automatic 3D analysis software for evaluating the response to systemic therapy
Autor: | G. Dilorenzo, Cornacchia I, Stabile Ianora Aa, M. Moschetta, Giuseppe Angelelli, Di Giovanni G, Michele Telegrafo |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Target lesion
Male Carcinoma Hepatocellular 3d analysis Systemic therapy Sensitivity and Specificity Text mining Predictive Value of Tests Multidetector Computed Tomography medicine Humans Neoplasm Invasiveness Response Evaluation Criteria in Solid Tumors Aged Retrospective Studies business.industry Liver Neoplasms Middle Aged medicine.disease Hepatocellular carcinoma Disease Progression Original Article business Nuclear medicine Tomography X-Ray Computed Kappa Progressive disease Follow-Up Studies |
Popis: | AIM To evaluate the role of 320-detector row computed tomography (MDCT) with 3D analysis software in follow up of patients affected by multicentric hepatocellular carcinoma (HCC) treated with systemic therapy by using modified response evaluation criteria in solid tumors (mRECIST). PATIENTS AND METHODS 38 patients affected by multicentric HCC underwent MDCT. All exams were performed before and after iodinate contrast material intravenous injection by using a 320-detection row CT device. CT images were analyzed by two radiologists using multi-planar reconstructions (MPR) in order to assess the response to systemic therapy according to mRECIST criteria: complete response (CR), partial response (PR), progressive disease (PD), stable disease (SD). 30 days later, the same two radiologists evaluated target lesion response to systemic therapy according to mRECIST criteria by using 3D analysis software. The difference between the two systems in assessing HCC response to therapy was assessed by the analysis of the variance (Anova Test). Interobserver agreement between the two radiologists by using MPR images and 3D analysis software was calculated by using Cohen's Kappa test. RESULTS PR occurred in 10/38 cases (26%), PD in 6/38 (16%), SD in 22/38 (58%). Anova Test showed no statistically significant difference between the two systems for assessing target lesion response to therapy (p >0.05). Inter-observer agreement (k) was respectively of 0.62 for MPR images measurements and 0.86 for 3D analysis ones. CONCLUSIONS 3D Analysis software provides a semiautomatic system for assessing target lesion response to therapy according to mRECIST criteria in patient affected by multifocal HCC treated with systemic therapy. The reliability of 3D analysis software makes it useful in the clinical practice. |
Databáze: | OpenAIRE |
Externí odkaz: |